Solana Co. (HSDT) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Reporting Period: Quarter ended September 30, 2025.
Company Status: Formerly Helius Medical Technologies, Inc., the company rebranded to Solana Company in September 2025. It operates as a dual-purpose entity: a neurotechnology firm commercializing the PoNS device and a Digital Asset Treasury (DAT) focused on acquiring and holding Solana (SOL) tokens.
Capital Structure: The company executed two reverse stock splits in 2025 (1-for-15 in May and 1-for-50 in July). As of November 17, 2025, 41,301,400 shares of Class A common stock were outstanding.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $697 | $51 | $789 | $368 |
| Gross Profit | $594 | $(136) | $469 | $(60) |
| Net Loss | $(352,768) | $(3,686) | $(366,441) | $(7,814) |
| Loss Per Share (Diluted) | $(32.89) | $(744.35) | $(90.14) | $(2,507.81) |
| Cash & Equivalents | $124,051 | $1,088 | (Balance Sheet) | |
| Working Capital | $122,524 | $1,261 | ||
| Digital Assets (SOL) | $350,175 | $0 | (Balance Sheet) | |
| Derivative Liability | $625,173 | $241 |
Material Changes vs. Prior Period
- Strategic Pivot: The company transitioned from a pre-revenue medical device stage to an active SOL treasury. It holds 1.74 million SOL tokens valued at $350.2 million as of September 30, 2025.
- Capital Raise: In September 2025, the company completed a $502.8 million PIPE offering (including $113 million in digital assets), resulting in $374.9 million in net cash proceeds. This alleviated prior "substantial doubt" regarding going concern status.
- Revenue Growth: Revenue increased 1,267% QoQ (vs. prior year) driven by new staking rewards ($342k) and increased PoNS sales. However, operating expenses surged due to the new treasury strategy.
- Non-GAAP Volatility: The massive net loss is primarily driven by non-cash items: a $545.7 million loss on derivative liability (initial recognition of warrants) and a $30.5 million unrealized loss on digital assets due to SOL price fluctuations.
- Liquidity: Cash and cash equivalents increased from $1.1 million to $124.1 million, funded almost entirely by financing activities ($400.7 million net cash provided).
Guidance, Outlook, and Risks
- Outlook: Management expects to scale SOL holdings over the next 12-24 months using ATM offerings and other capital strategies. The company plans to leverage SOL's native staking yield (~7%) and DeFi opportunities.
- Subsequent Events: Post-period, SOL prices declined 37% (from $208.70 to $131.00). The company purchased an additional 587,737 SOL. A $100 million stock repurchase program was approved in November 2025.
- Key Risks:
- Asset Concentration: Financial results are heavily dependent on the volatile price of SOL.
- Regulatory: Risk of SOL being classified as a security, which could force the company to register as an investment company under the 1940 Act.
- Custody & Cyber: Risks related to third-party custodians, smart contract vulnerabilities, and potential loss of private keys.
- Derivative Liability: Significant exposure to changes in fair value of stapled warrants, which are classified as liabilities and marked-to-market quarterly.
Investor Verification Checklist
- Verify the valuation methodology for the $625 million derivative liability and the impact of stock price volatility on future earnings.
- Confirm the custody arrangements for the $350 million SOL holding and the specific insurance coverage against theft or loss.
- Review the terms of the "Stapled Warrants" issued in the PIPE to understand dilution risks and settlement conditions.
- Monitor the progress of PoNS reimbursement approvals (Medicare/Commercial) to assess the viability of the legacy medical business alongside the treasury strategy.
- Assess the company's ability to maintain Nasdaq listing compliance given the history of reverse splits and equity requirements.